Literature DB >> 1316478

Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes.

L Qu1, D T Rowe.   

Abstract

In this study of Epstein-Barr virus (EBV) latency, the polymerase chain reaction was used in modified form for amplification and detection of viral mRNA sequences in peripheral blood lymphocytes from healthy seropositive adults. Six known promoters for latent gene expression and eight known gene products were identified in in vitro-immortalized lymphocytes and in the cell lines established spontaneously from seropositive adults. We examined whether mRNA expression in uncultured B cells from four seropositive adults was the same as that which occurred in spontaneously established EBV-positive B-cell lines from the same individuals. A minimum of 17 polymerase chain reaction targets was required to circumscribe the known latent mRNA structures. Expression of the C promoter for the EBNA genes was detected in B-cell RNA from three of the four subjects. Transcripts initiated from the alternative W promoter for EBNA expression were not detected. The spliced transcripts detected in the B cells contained only the C2-to-W1 alternative splice, which was nonproductive for EBNA4 gene expression. None of the other EBNA open reading frames were detected spliced onto the 3' ends of the C promoter-initiated RNAs. Spliced RNA from the TP gene was detected in all four subjects. Expression of the TP gene was restricted to TP1 promoter-initiated RNAs, as no TP2 promoter-initiated transcripts were detected. Expression of RNA from the LMP gene was not detected. The F promoter which is active in the restricted expression latency that occurs in Burkitt's lymphoma cells was not detected being expressed in peripheral blood B cells. This pattern of latent gene expression is unique to uncultured B cells, indicating that there are profound differences between viral latent states in vitro and in situ and suggesting a central role for the TP gene in the latency of EBV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316478      PMCID: PMC241156     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  An Epstein-Barr virus transcription unit is at least 84 kilobases long.

Authors:  M Bodescot; O Brison; M Perricaudet
Journal:  Nucleic Acids Res       Date:  1986-03-25       Impact factor: 16.971

2.  An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide.

Authors:  S H Speck; A Pfitzner; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

4.  Differential expression of Epstein Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells.

Authors:  P R Smith; B E Griffin
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

5.  An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase.

Authors:  R Longnecker; B Druker; T M Roberts; E Kieff
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Identification of the Epstein-Barr virus terminal protein gene products in latently infected lymphocytes.

Authors:  D T Rowe; L Hall; I Joab; G Laux
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes.

Authors:  M Woisetschlaeger; C N Yandava; L A Furmanski; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

8.  Early events in Epstein-Barr virus infection of human B lymphocytes.

Authors:  C Alfieri; M Birkenbach; E Kieff
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

9.  Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection.

Authors:  M Woisetschlaeger; X W Jin; C N Yandava; L A Furmanski; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

10.  Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: a consequence of immune surveillance or a phenotypic vestige of the progenitor cells?

Authors:  S Torsteinsdottir; C Brautbar; G Klein; E Klein; M G Masucci
Journal:  Int J Cancer       Date:  1988-06-15       Impact factor: 7.396

View more
  91 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 3.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

4.  Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan.

Authors:  M Tanaka; Y Kawaguchi; J Yokofujita; M Takagi; Y Eishi; K Hirai
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

5.  Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

Authors:  L Zhang; J S Pagano
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

6.  Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils.

Authors:  A M Joseph; G J Babcock; D A Thorley-Lawson
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.

Authors:  R Swart; I K Ruf; J Sample; R Longnecker
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Latent antigen vaccination in a model gammaherpesvirus infection.

Authors:  E J Usherwood; K A Ward; M A Blackman; J P Stewart; D L Woodland
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal.

Authors:  L Matskova; I Ernberg; T Pawson; G Winberg
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development.

Authors:  Toni Portis; Richard Longnecker
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.